- Home
- MNOV vs WHF Comparison
MNOV vs WHF Comparison
Compare MNOV & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNOV | WHF |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 152.5M |
| IPO Year | 2004 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MNOV | WHF |
|---|---|---|
| Price | $2.64 | $7.12 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 2 |
| Target Price | $7.50 | ★ $7.75 |
| AVG Volume (30 Days) | ★ 683.6K | 91.6K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.67% |
| EPS Growth | N/A | ★ 31.91 |
| EPS | N/A | ★ 0.44 |
| Revenue | ★ $2,360,807.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $180.00 | N/A |
| P/E Ratio | ★ N/A | $16.05 |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $6.07 |
| 52 Week High | $3.90 | $7.84 |
Technical Indicators
Market Signals| Indicator | MNOV | WHF |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 45.71 |
| Support Level | $1.28 | $6.85 |
| Resistance Level | $3.90 | $7.22 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 43.06 | 1.79 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.